Liokast-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated for the effective management of allergic conditions. Levocetirizine is a potent, non-sedating antihistamine that selectively inhibits peripheral H1 receptors, thereby alleviating symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria associated with allergic rhinitis and chronic idiopathic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene receptor, reducing inflammation and bronchoconstriction in the airways, making it beneficial in the prophylaxis and chronic treatment of asthma and allergic rhinitis. The synergistic action of these two agents provides comprehensive relief from allergic symptoms by targeting multiple inflammatory pathways. Liokast-M is indicated for patients requiring simultaneous control of allergic rhinitis and asthma or chronic urticaria. It is well-tolerated, with a favorable safety profile, though caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. Dosage should be individualized based on clinical response and severity of symptoms. Liokast-M Tablet should be used under medical supervision, with adherence to prescribed dosage to optimize therapeutic outcomes and minimize adverse effects.